Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desloratadine added to neoadjuvant chemotherapy in breast cancer
IRCT20230221057485N1Phase 2Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of desloratadine in breast cancer (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoint: Treatment response by RECIST. Started Aug 2023; status: completed.
02
Drugs
desloratadine
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20230221057485N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230221057485N1.